CoChat

High-grade glioma before and after treatment with radiation and Avastin: Initial observations

Open access
Fischer, Ingeborg, Cunliffe, Clare H., Bollo, Robert J., Raza, Shahzad, Monoky, David, Chiriboga, Luis, Parker, Erik C., Golfinos, John G., Kelly, Patrick J., Knopp, Edmond A., Gruber, Michael L., Zagzag, David, Narayana, Ashwatha · 2008 · Neuro-Oncology
Cited by 79

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

We evaluate the effects of adjuvant treatment with the angiogenesis inhibitor Avastin (bevacizumab) on pathological tissue specimens of high-grade glioma. Tissue from five patients before and after treatment with Avastin was subjected to histological evaluation and compared to four control cases of glioma before and after similar treatment protocols not including bevacizumab. Clinical and radiographic data were reviewed. Histological analysis focused on microvessel density and vascular morphology, and expression patterns of vascular endothelial growth factor-A (VEGF-A) and the hematopoietic stem cell, mesenchymal, and cell motility markers CD34, smooth muscle actin, D2-40, and fascin. All patients with a decrease in microvessel density had a radiographic response, whereas no response was seen in the patients with increased microvessel density. Vascular morphology showed apparent "normalization" after Avastin treatment in two cases, with thin-walled and evenly distributed vessels. VEGF-A expression in tumor cells was increased in two cases and decreased in three and did not correlate with treatment response. There was a trend toward a relative increase of CD34, smooth muscle actin, D2-40, and fascin immunostaining following treatment with Avastin. Specimens from four patients with recurrent malignant gliomas before and after adjuvant treatment (not including bevacizumab) had features dissimilar from our study cases. We conclude that a change in vascular morphology can be observed following antiangiogenic treatment. There seems to be no correlation between VEGF-A expression and clinical parameters. While the phenomena we describe may not be specific to Avastin, they demonstrate the potential of tissue-based analysis for the discovery of clinically relevant treatment response biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1215/15228517-2008-042

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 79

Metadata

Authors
Fischer, I., Cunliffe, C. H., Bollo, R. J., Raza, S., Monoky, D., Chiriboga, L., Parker, E. C., Golfinos, J. G., Kelly, P. J., Knopp, E. A., Gruber, M. L., Zagzag, D., & Narayana, A.
Venue
Neuro-Oncology
Published
2008-10-01
Volume
10
Issue
5
Pages
700-708
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2103796195
Cited by
79
References
2
FWCI
3.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-grade glioma before and after treatment with radiation and Avastin: Initial observations. https://app.cochat.ai/papers/10.1215/15228517-2008-042
The paper
Fischer, I., Cunliffe, C. H., Bollo, R. J., Raza, S., Monoky, D., Chiriboga, L., Parker, E. C., Golfinos, J. G., Kelly, P. J., Knopp, E. A., Gruber, M. L., Zagzag, D., & Narayana, A. (2008). High-grade glioma before and after treatment with radiation and Avastin: Initial observations. Neuro-Oncology. https://doi.org/10.1215/15228517-2008-042

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.